Search - tctmd.com

Displaying 381 - 400 of 582

Sort: Relevancy | Date

News Daily News

Expert Consensus Highlights Needs of Cancer Patients in the Cath Lab and Beyond

L.A. McKeown

January 12, 2016

News Daily News

High Level of Gut Metabolite Predicts Worse Outcomes in ACS Patients

Michael O'Riordan

January 12, 2016

News Industry News

Penumbra Introduces POD® Packing Coil for the Embolization of Peripheral Vessels and Aneurysms

January 05, 2016

News Daily News

三联疗法特别是普拉格雷会增加急性心梗患者的出血风险

Yael L. Maxwell

December 22, 2015

News Daily News

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

Yael L. Maxwell

December 22, 2015

News Daily News

El Tratamiento Triple, sobre todo con Prasugrel, Aumenta el Riesgo Hemorrágico de los IAM

Yael L. Maxwell

December 22, 2015

News Daily News

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Yael L. Maxwell

December 14, 2015

News Daily News

Surgery Common in Stented Patients But Newer Stents Appear to Reduce Potential Risks

Michael O'Riordan

December 07, 2015

News Daily News

一项观察性研究表明，患者在急性心肌梗死后服用PUFA可真正受益

November 30, 2015

News Daily News

Un Estudio Observacional Revela los Beneficios Reales de Pacientes a Tratamiento con AGPI Post-IAM

November 30, 2015

News Daily News

Observational Study Hints at Real Benefits for Patients Who Take PUFAs After Acute MI

November 30, 2015

News Industry News

Boston Scientific Receives FDA Approval And CE Mark For AngioJet™ ZelanteDVT™ Thrombectomy Catheter

November 30, 2015

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

News Daily News

Morphine’s Worrisome Effects on Ticagrelor Affirmed in Pharmacokinetic Study

Shelley Wood

October 29, 2015

News Daily News

Goodbye BMS? New DAPT Analysis Shows Less Stent Thrombosis With DES

Yael L. Maxwell

October 26, 2015

News Industry News

One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015

October 20, 2015

News Conference News TCT 2015

Darbepoetin Plus Iron Fails to Reduce Transfusion Rates After TAVR in Anemia Patients

October 13, 2015

News Daily News

Cerebral Embolization Greater When Valvuloplasty Not Done Before TAVR

Todd Neale

September 21, 2015

News Industry News

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

September 16, 2015

News Conference News ESC 2015

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

Caitlin E. Cox

September 02, 2015

Advertisement

Expert Consensus Highlights Needs of Cancer Patients in the Cath Lab and Beyond

High Level of Gut Metabolite Predicts Worse Outcomes in ACS Patients

Penumbra Introduces POD® Packing Coil for the Embolization of Peripheral Vessels and Aneurysms

三联疗法特别是普拉格雷会增加急性心梗患者的出血风险

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

El Tratamiento Triple, sobre todo con Prasugrel, Aumenta el Riesgo Hemorrágico de los IAM

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Surgery Common in Stented Patients But Newer Stents Appear to Reduce Potential Risks

一项观察性研究表明，患者在急性心肌梗死后服用PUFA可真正受益

Un Estudio Observacional Revela los Beneficios Reales de Pacientes a Tratamiento con AGPI Post-IAM

Observational Study Hints at Real Benefits for Patients Who Take PUFAs After Acute MI

Boston Scientific Receives FDA Approval And CE Mark For AngioJet™ ZelanteDVT™ Thrombectomy Catheter

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Morphine’s Worrisome Effects on Ticagrelor Affirmed in Pharmacokinetic Study

Goodbye BMS? New DAPT Analysis Shows Less Stent Thrombosis With DES

One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015

Darbepoetin Plus Iron Fails to Reduce Transfusion Rates After TAVR in Anemia Patients

Cerebral Embolization Greater When Valvuloplasty Not Done Before TAVR

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content